New targeted therapy zolbetuximab extends survival for patients with advanced gastric cancer

An international phase 3 clinical trial, done in participation with Weill Cornell Medicine and NewYork-Presbyterian, found that a new targeted treatment called zolbetuximab, given in combination with a standard chemotherapy, extended survival for patients with advanced gastric or gastroesophageal junction cancer that overexpressed a specific biomarker.

Coffee and COVID: Study finds coffee inhibits SARS-CoV-2, offers new dietary defense strategy

Study discovers that coffee, especially its bioactive compounds like chlorogenic acids, can inhibit SARS-CoV-2 entry and reduce ACE2 and TMPRSS2 levels, indicating that coffee intake

November 17, 2023

Diabetes tech firms focusing on Type 2 patients

Diabetes technology companies remain focused on Type 2 diabetes as a source of growth. Despite the questions from investors on GLP-1 drugs that have peppered

November 7, 2023

CureVac and MD Anderson Enter Strategic Collaboration to Develop Novel Cancer Vaccines – Biotech Investments

Issuer: CureVac / Key word(s): Alliance 16.04.2024 / 13:00 CET/CEST The issuer is solely responsible for the content of this announcement. CureVac and MD Anderson

April 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.